S3 File - by Andrei Rajkovic (10965915)

(A–D) Representative immunoblots for the reporter assays shown in Fig 4A–D. by Lorenza Cutrone (21144285)

Synthesis and Spectroscopic Investigation of a Series of Push–Pull Boron Dipyrromethenes (BODIPYs) by Sunting Xuan (1494469)

“…All BODIPYs were nontoxic in the dark (IC₅₀ > 200 μM) and showed low phototoxicity (IC₅₀ > 100 μM, 1.5 J/cm²) toward human HEp2 cells. …”

Brain regions with significant metabolic inhibition (p < 0.001, K = 50) (A) and activation (B) in rats following cocaine self-administration compared to baseline. Cluster location... by Christopher Rowan (21499924)

R-loop accumulation at the origins of gene bodies in SAMHD1-deficient AGS patient fibroblasts. by Kiwon Park (6492266)

Niphatenones block N/C interaction and inhibit expression of AR regulated genes. by Carmen A. Banuelos (636867)

Inverse Phase Transition in Droplet Clusters Levitating over the Locally Heated Water Layer by Alexander A. Fedorets (7376702)

“…Self-assembled microdroplet clusters can levitate above a locally heated water surface. Normally, the temperature of droplets is in the range of 50–95 °C. …”

Inverse Phase Transition in Droplet Clusters Levitating over the Locally Heated Water Layer by Alexander A. Fedorets (7376702)

“…Self-assembled microdroplet clusters can levitate above a locally heated water surface. Normally, the temperature of droplets is in the range of 50–95 °C. …”

Inverse Phase Transition in Droplet Clusters Levitating over the Locally Heated Water Layer by Alexander A. Fedorets (7376702)

“…Self-assembled microdroplet clusters can levitate above a locally heated water surface. Normally, the temperature of droplets is in the range of 50–95 °C. …”

WBC isolation using a dynamically CPSV (Disc D). by David J. Kinahan (2742811)

Settling time for changes in the median of the Folded Normal distribution. by Ariel Burman (20329776)

Anthelmintics Derived from the Kinase Inhibitor SGI-1776 for the Treatment of Gastrointestinal Worm Infections by Mostafa A. Elfawal (22430138)

“…We demonstrate the efficacy of optimized compound <b>50</b> as a new oral anthelmintic, which demonstrated better gut restriction properties and significantly reduced the fecundity of T. muris whipworm adults in infected mice. …”

Mean scores of IB-DE, IH-DE, and IB-DE items in Sample 1 and Sample 2 as well as women and men across the samples. by Aistė Ambrasė (22505574)

Fig 4 - by Hyuk Sung Yoon (20208672)

DataSheet5_First-Line ICI Monotherapies for Advanced Non-small-cell Lung Cancer Patients With PD-L1 of at Least 50%: A Cost-Effectiveness Analysis.docx by Qiao Liu (346535)

“…</p><p>Conclusion: For advanced NSCLC patients with PD-L1 of at least 50%, cemiplimab was a cost-effective option compared with pembrolizumab and a dominant alternative against atezolizumab. …”

DataSheet2_First-Line ICI Monotherapies for Advanced Non-small-cell Lung Cancer Patients With PD-L1 of at Least 50%: A Cost-Effectiveness Analysis.docx by Qiao Liu (346535)

“…</p><p>Conclusion: For advanced NSCLC patients with PD-L1 of at least 50%, cemiplimab was a cost-effective option compared with pembrolizumab and a dominant alternative against atezolizumab. …”

DataSheet3_First-Line ICI Monotherapies for Advanced Non-small-cell Lung Cancer Patients With PD-L1 of at Least 50%: A Cost-Effectiveness Analysis.docx by Qiao Liu (346535)

“…</p><p>Conclusion: For advanced NSCLC patients with PD-L1 of at least 50%, cemiplimab was a cost-effective option compared with pembrolizumab and a dominant alternative against atezolizumab. …”

DataSheet1_First-Line ICI Monotherapies for Advanced Non-small-cell Lung Cancer Patients With PD-L1 of at Least 50%: A Cost-Effectiveness Analysis.docx by Qiao Liu (346535)

“…</p><p>Conclusion: For advanced NSCLC patients with PD-L1 of at least 50%, cemiplimab was a cost-effective option compared with pembrolizumab and a dominant alternative against atezolizumab. …”

DataSheet6_First-Line ICI Monotherapies for Advanced Non-small-cell Lung Cancer Patients With PD-L1 of at Least 50%: A Cost-Effectiveness Analysis.docx by Qiao Liu (346535)

“…</p><p>Conclusion: For advanced NSCLC patients with PD-L1 of at least 50%, cemiplimab was a cost-effective option compared with pembrolizumab and a dominant alternative against atezolizumab. …”

DataSheet4_First-Line ICI Monotherapies for Advanced Non-small-cell Lung Cancer Patients With PD-L1 of at Least 50%: A Cost-Effectiveness Analysis.docx by Qiao Liu (346535)

“…</p><p>Conclusion: For advanced NSCLC patients with PD-L1 of at least 50%, cemiplimab was a cost-effective option compared with pembrolizumab and a dominant alternative against atezolizumab. …”